Item 2. Properties
Item 2. PROPERTIES
As of December 31, 2025, we owned or leased approximately 160 properties. The locations and primary functions of significant properties are summarized in the following tables:
U.S. Location: Manufacturing Administrative R&D Sales and marketing
Warehouse Distribution center
Thousand Oaks, CA (1)
x
x
x
x
x
x
Juncos, Puerto Rico x
x
x
x
West Greenwich, RI x
x
x
Deerfield, IL
x
x
x
Cambridge, MA x
New Albany, OH
x
x
x
San Francisco, CA x
Tampa, FL x
x
Louisville, KY x
x
Other U.S. cities (2)
x
x
x
ROW Location: Manufacturing Administrative R&D Sales and marketing
Warehouse Distribution center
Canada x
x
x
China x
x
Denmark x
x
x
Germany x x x
Iceland x x
India
x
Ireland x
x
x
x
x
Netherlands x
x
x
x
x
Singapore x
x
x
x
Other countries (2)
x
x
x
x
____________
(1) Corporate headquarters.
(2) Includes smaller properties in other U.S. and ROW locations, primarily for administrative and sales and marketing.
Excluded from the information above are (i) undeveloped land and leased properties that have been abandoned and (ii) certain buildings we still own but that are no longer used in our business. Additionally, in 2025 we broke ground on our second drug substance manufacturing facility in Holly Springs, North Carolina; announced expansions of our manufacturing network in Ohio and the U.S. territory of Puerto Rico; and broke ground on a new, state-of-the-art science and innovation center at our corporate headquarters in Thousand Oaks, California. There are no material encumbrances on our owned properties.
We believe our facilities are suitable for their intended uses and, in conjunction with our third-party contract manufacturing agreements, provide adequate capacity and are sufficient to meet our expected needs. See Item 1A. Risk Factors for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.
See Item 1. Business—Manufacturing, Distribution and Raw Materials.
Item 3. LEGAL PROCEEDINGS
Certain of the legal proceedings in which we are involved are discussed in Part IV—Note 20, Contingencies and commitments, to the Consolidated Financial Statements and are hereby incorporated by reference.
57
Item 4. MINE SAFETY DISCLOSURES
Not applicable.
58
PART II
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.